# Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

> **NCT00080015** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 9 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Diflomotecan (BN80915)

## Key facts

- **NCT ID:** NCT00080015
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-12
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080015, "Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00080015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*